Shares of Sangamo Therapeutics (NASDAQ:SGMO) rose 12% in post-market trading Tuesday after the company announced the FDA had ...

Sangamo Therapeutics said the Food and Drug Administration has cleared its investigational new drug application for its ST-400 treatment for intractable pain due to idiopathic small fiber neuropathy.

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

Neuralgia, characterized by acute paroxysmal pain radiating along the course of one or more nerves, is a significant concern ...